Pharmacological and clinical aspects of fluvoxamine (Depromel), the first selective serotonin reuptake inhibitor approved for clinical use employed in Japan

• Published in: Nihon yakurigaku zasshi Vol. 115; no. 5; p. 271
• Main Authors: Hachisu, M, Ichimaru, Y
• Format: Journal Article
• Language: Japanese
• Published: Japan 2000
• Subjects: Animals; Depression - drug therapy; Disease Models, Animal; Drug Approval; Fluvoxamine - pharmacokinetics; Fluvoxamine - therapeutic use; Humans; Japan; Mice; Obsessive-Compulsive Disorder - drug therapy; Receptors, Neurotransmitter - metabolism; Serotonin Uptake Inhibitors - pharmacokinetics; Serotonin Uptake Inhibitors - therapeutic use; Time Factors; Japan
• ISSN: 0015-5691
• DOI: 10.1254/fpj.115.271

Fluvoxamine (Depromel), a selective serotonin reuptake inhibitor (SSRI), was launched in May 1999 in Japan with more than 10 years' delay from the marketing in Europe and the United States. Fluvoxamine has been approved in about 80 countries as the indication to "depression" since 1983. As the indication to obsessive-compulsive disorder (OCD), fluvoxamine was first approved in the United States in 1994 and then in about 30 countries. Efficacy of the drug on "depression and depressed state" was found to be comparable to traditional tricyclic antidepressants (TCAs) by the clinical studies in Japan. Indication to OCD was first approved for fluvoxamine in Japan. The antidepressant and the anti-OCD action are considered the result of the serotonin reuptake inhibition at the serotonergic neurons. Fluvoxamine has little affinity for muscarinic, adrenergic alpha 1- and histamine H1-receptors, which TCAs have. Therefore, fluvoxamine possesses less side effects such as dry mouse, disuria, dizziness, orthostatic hypotension and drowsiness, etc.; and it is useful for elderly patients and long-term treatments for depression and OCD.